• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by MannKind Corporation

    5/13/25 4:02:55 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001297976
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    MANNKIND CORPORATION
    SEC File Number
    000-50865
    Address of Issuer
    1 Casper Street
    Danbury
    CONNECTICUT
    06810
    Phone
    (818) 661-5000
    Name of Person for Whose Account the Securities are To Be Sold
    DAVID THOMSON
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    32179150716.7830393285205/13/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/10/2025Restricted StockISSUERCheckbox not checked304105/10/2025Not Applicable
    Common05/10/2025Performance SharesISSUERCheckbox not checked2913805/10/2025Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/13/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/19/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ David Bruce Thomson

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MNKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    12/20/2024$9.00Overweight
    Wells Fargo
    12/19/2024$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    9/9/2024$7.00 → $8.00Outperform
    Leerink Partners
    6/13/2024$8.00Buy
    Rodman & Renshaw
    10/10/2023$10.00Outperform
    Wedbush
    2/28/2022$6.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNKD
    Leadership Updates

    Live Leadership Updates

    See more
    • MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

      MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

      1/5/22 6:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a "Future Ready" symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of A

      6/9/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

      WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit. Daly will share his personal story of being diagnosed with diabetes as a teen and how he does not let it keep him from living life without limits. The former karting champion will also provide some karting tips and then race go-karts to identify the Fastest 6. Daly was first diagnosed with diabetes at the age of 14, and today is the only known U.S. professional r

      5/27/25 9:15:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind to Present at Upcoming Investor Conferences

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City: RBC Capital Markets 2025 Global Annual Healthcare Conference Tuesday, May 20, 8:00 a.m. ET Jefferies Global Healthcare Conference Thursday, June 5,

      5/13/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    SEC Filings

    See more
    • MannKind Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/19/25 5:02:22 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by MannKind Corporation

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/15/25 4:08:08 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by MannKind Corporation

      144 - MANNKIND CORP (0000899460) (Subject)

      5/13/25 4:02:55 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Mannkind with a new price target

      Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00

      4/10/25 12:42:30 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Mannkind with a new price target

      Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00

      2/10/25 7:01:41 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Mannkind with a new price target

      Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00

      12/20/24 7:44:06 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Binder Steven B. sold $256,340 worth of shares (64,085 units at $4.00), decreasing direct ownership by 6% to 925,258 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      6/10/25 8:07:37 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP Chief Medical Officer Blank Burkhard covered exercise/tax liability with 15,630 shares, decreasing direct ownership by 3% to 465,124 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      5/27/25 7:26:54 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by EVP Chief Medical Officer Blank Burkhard

      4/A - MANNKIND CORP (0000899460) (Issuer)

      5/27/25 7:25:56 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care